← FDA DRUG APPROVALS

FDA ANDA · ANDA076102

LISINOPRIL

Sponsor: COREPHARMA

APPLICATION
ANDA076102
TYPE
ANDA
ORIGINAL APPROVAL
2002-09-30
LATEST ACTION
2020-04-29
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LISINOPRILPrescription
LISINOPRIL 5MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 30MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 10MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 2.5MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 40MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 20MG · TABLET · ORAL

Approval history

2020-04-29Labeling · Supplement 16 · standardAP
2016-07-13Labeling · Supplement 15 · standardAP
2016-07-13Labeling · Supplement 13 · standardAP
2016-07-13Labeling · Supplement 11 · standardAP
2016-07-13Labeling · Supplement 14 · standardAP
2016-07-13Labeling · Supplement 12 · standardAP
2013-08-16Labeling · Supplement 10 · standardAP
2008-08-22Labeling · Supplement 6AP
2006-06-08Labeling · Supplement 5AP
2002-09-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →